Financial Performance - Reported Net Income increased by 19% year-over-year to $11.3 million[12] - Adjusted Net Income increased by 27% year-over-year to $12.0 million[12] - EBITDA increased by 6% year-over-year to $50.6 million[12] - Adjusted EBITDA increased by 8% year-over-year to $51.4 million[12] - Free Cash Flow decreased by 62% year-over-year to $11.2 million, impacted by higher working capital[10, 12] Volume and Sales - Global sales volume grew 1% year-over-year, driven by Polymers, Crop Productivity, and MCT business, offset by decline in commodity consumer surfactants[9] - Surfactants Adjusted EBITDA decreased by 1% to $34.5 million due to lower demand in commodity consumer end markets, offset by growth in agricultural and oilfield end markets[20, 25] - Polymers Adjusted EBITDA increased by 17% to $25.6 million, driven by sales volume growth in North America and Europe[20, 30] - Specialty Products Adjusted EBITDA decreased by $2.1 million primarily due to order timing fluctuations within the pharmaceutical business[20] Strategic Initiatives - The Pasadena, Texas site is now operational and expected to provide benefits in the specialty alkoxylation business[11, 41] - The company is on track to close the sale of Philippines assets during the fourth quarter[11]